CVE:NXG - NexgenRx Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.37
▲ +0.03 (8.82%)
1 month | 3 months | 12 months
Get New NexgenRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NXG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NexgenRx in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.37.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in NexgenRx. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/13/2020Canaccord GenuitySet Price TargetSpeculative BuyC$4.00
i
(Data available from 4/21/2016 forward)
NexgenRx logo
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. It offers prescription drug claims; dental claims; and claims for extended health benefits, as well as provides a health care spending account that offers an amount of money to an individual to pay for health or dental benefits. The company also provides individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; direct deposit services; and ancillary services. NexgenRx Inc. was founded in 2003 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: C$0.37
C$0.36
C$0.60

50 Day Range

MA: C$0.31
C$0.27
C$0.37

52 Week Range

Now: C$0.37
C$0.14
C$0.60

Volume

94,250 shs

Average Volume

30,284 shs

Market Capitalization

C$26.02 million

P/E Ratio

12.76

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NexgenRx?

The following Wall Street analysts have issued stock ratings on NexgenRx in the last twelve months:
View the latest analyst ratings for NXG.

What is the current price target for NexgenRx?

0 Wall Street analysts have set twelve-month price targets for NexgenRx in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for NexgenRx in the next year.
View the latest price targets for NXG.

What is the current consensus analyst rating for NexgenRx?

NexgenRx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NXG.

What other companies compete with NexgenRx?

How do I contact NexgenRx's investor relations team?

NexgenRx's physical mailing address is 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada. The company's listed phone number is +1-416-6953393. The official website for NexgenRx is www.nexgenrx.com.